Project Details
Description
”RCD405 is quinoline-derived small molecular compound. In the project, possible anti-inflammatory and bronchorelaxant properties are investigated in models related to asthma and COPD. This could have bearing on future treatment of these diseases since RCD405 probably acts via pathways other than those used by current treatment options.”
| Status | Active |
|---|---|
| Effective start/end date | 2023/04/03 → 2025/12/31 |
Collaborative partners
- Lund University
- Arcede Pharma AB (lead)
Funding
- Swedish Government Agency for Innovation Systems (Vinnova)
